Kisqali
UK's MHRA Approves Kisqali, Aromatase Inhibitor in Early-Stage Breast Cancer
The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.
Novartis Posts Strong Q4 Sales of Kisqali, Pluvicto
During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.
Novartis Sees Steady Q3 Pluvicto Sales Growth as it Readies to Triple Eligible Population in 2025
Premium
The Swiss drugmaker is gearing up to meet a surge in patient demand for the radiopharmaceutical if the FDA approves it in an earlier-line prostate cancer setting.
Jul 18, 2024
May 21, 2024